Highly active antiretroviral therapy-associated metabolic syndrome and cardiovascular risk

Chemotherapy

Volumn 52, Issue 4, 2006, Pages 161-165

  Barbaro, Giuseppe ^a,c   Barbarini, Giorgio ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

^c NONE   (Italy)

Author keywords

Cardiovascular disease; Highly active antiretroviral therapy; Human immunodeficiency virus; Metabolic syndrome

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; EFAVIRENZ; PROTEINASE INHIBITOR; ZIDOVUDINE;

ADIPOCYTE; BLOOD CLOTTING DISORDER; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DISORDERS OF MITOCHONDRIAL FUNCTIONS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LIPODYSTROPHY; METABOLIC SYNDROME X; MITOCHONDRION; PATHOGENESIS; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; REVIEW;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CARDIOVASCULAR DISEASES; HIV INFECTIONS; HUMANS; METABOLIC SYNDROME X; RISK FACTORS;

EID: 33745068786     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000093034     Document Type: Review

References (45)

1. Carr A: HIV lipodystrophy: risk factors, pathogenesis, diagnosis and management. AIDS 2003;17(suppl 1):S141-S148.
2. Carr A, Samaras K, Chisholm DJ, Cooper DA: Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 1998;351:1881-1883.
3. Mooser V, Carr A: Antiretroviral therapy-associated hyperlipidemia in HIV disease. Curr Opin Lipidol 2001;12:313-319.
4. Fauvel J, Bonnet E, Ruidavets JB, Ferrières J, Toffoletti A, Massip P, Chap H, Perret B: An interaction between apo C-III variants and protease inhibitors contributes to high triglyceride/low HDL levels in treated HIV patients. AIDS 2001;15:2397-2406.
5. Caron M, Auclair M, Sterlingot H, Kornprobst M, Capeau J: Some HIV protease inhibitors alter lamin A/C maturation and stability, SREBP-1 nuclear localization and adipocyte differentiation. AIDS 2003;17:2437-2444.
6. Murata H, Hruz PW, Mueckler M: The mechanism of insulin resistance caused by HIV protease inhibitor therapy. J Biol Chem 2000;275:20251-20254.
7. Mynarcik DC, McNurlan MA, Steigbigel RT, Fuhrer J, Gelato MC: Association of severe insulin resistance with both loss of limb fat and elevated serum tumor necrosis factor receptor levels in HIV lipodystrophy. J Acquir Immune Defic Syndr 2000;25:312-321.
8. Gougeon ML, Penicaud L, Fromenty B, Leclercq P, Viard JP, Capeau J: Adipocytes targets and actors in the pathogenesis of HIV-associated lipodystrophy and metabolic alterations. Antivir Ther 2004;9:161-177.
9. Vigouroux C, Maachi M, Nguyen TH, Coussieu C, Gharakhanian S, Funahashi T, Matsuzawa Y, Shimomura I, Rozenbaum W, Capeau J, Bastard JP: Serum adipocytokines are related to lipodystrophy and metabolic disorders in HIV-infected men under antiretroviral therapy. AIDS 2003;17:1503-1511.
10. Haque WA, Shimomura I, Matsuzawa Y, Garg A: Serum adiponectin and leptin levels in patients with lipodystrophies. J Clin Endocrinol Metab 2002;87:2395-2398.
11. Addy CL, Gavrila A, Tsiodras S, Brodovicz B, Karchmer AW, Mantzoros CS: Hypoadiponectinemia is associated with insulin resistance, hypertriglyceridemia, and fat redistribution in human immunodeficienc virus-infected patients treated with highly active antiretroviral therapy. J Clin Endocrinol Metab 2003;88:627-636.
12. Kosmiski L, Kuritzkes D, Lichtenstein K, Eckel R: Adipocyte-derived hormone levels in HIV lipodystrophy. Antivir Ther 2003;8:9-15.
13. Caron M, Auclair M, Lagathu C, Lombes A, Walker U, Kornprobst M, Capeau J: The HIV-1 nucleoside reverse transcriptase inhibitors stavudine and zidovudine alter adipocyte functions in vitro. AIDS 2004;18:2127-2136.
14. McComsey GA, Paulsen D, Lonergan JT, Hessenthaler SM, Hoppel CL, Williams VC, Fisher RL, Cherry CL, White-Owen C, Thompson KA, Ross ST, Hernandez JE, Ross LL: Improvements in lipoatrophy, mitochondrial DNA levels and fat apoptosis after replacing stavudine with abacavir or zidovudine. AIDS 2005;19:15-23.
15. Guidelines for the Evaluation and Management of Dyslipidemia in Human Immunodeficiency Virus (HIV)-Infected Adults Receiving Antiretrovial Therapy: Recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trial Groups. Clin Infect Dis 2004;37:613-627.
16. Volberding P, Murphy R, Barbaro G, Barbarini G, Bruno R, Cirelli A, Currie P, Di Lorenzo G, Fantoni M, Filice G, Galli M, Grisorio B, Moroni M, Recusani F, Sacchi P, Scevola D, Torre D, Vittecoq D: The Pavia consensus statement. AIDS 2003;17(suppl 1):S170-S179.
17. Carr A, Hudson J, Chuan J, Mallal S, Law M, Hoj J, Doong N, French M, Smith D, Cooper DA: HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study. AIDS 2001;15:1811-1822.
18. Clumeck N, Goebel F, Rozenbaum W, Gerstoft J, Staszewski S, Montaner J, Johnson M, Gazzard BG, Stone C, Athisegaran R, Moore S: Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA. AIDS 2001;15:1517-1526.
19. Ruiz L, Negredo E, Domingo P, Paredes R, Francia E, Balague M, Gel S, Bonjoch A, Fumaz CR, Johnston S, Romeu J, Lange J, Clotet B: Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with HIV-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study. J AIDS 2001;27:229-236.
20. van der Valk M, Kastelein JJP, Murphy RL, van Leth F, Katlama C, Horban A, Glesby M, Behrens G, Clotet B, Stellato RK, Molhuizen HOF, Reiss P; Atlantic Study Team: Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. AIDS 2001;15:2407-2414.
21. Fisac C, Fumero E, Crespo M, Roson B, Ferrer E, Virgili N, Ribera E, Gatell JM, Podzamczer D: Metabolic benefits 24 months after replacing a protease inhibitor with abacavir, efavirenz or nevirapine. AIDS 2005;19:917-925.
22. Hadigan C, Yawetz S, Thomas A, Havers F, Sax PE, Grinspoon S: Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial. Ann Intern Med 2004;140:786-794.
23. Carr A, Workman C, Carey D, Rogers G, Martin A, Baker D, Wand H, Law M, Samaras K, Emery S, Cooper DA; Rosey investigators: No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial. Lancet 2004;363:429-438.
24. Fiala M, Murphy T, MacDougall J, Yang W, Luque A, Iruela-Arispe L, Cashman J, Buga G, Byrns RE, Barbaro G, Arthos J: HAART drugs induce mitochondrial damage and intracellular gaps and gp120 causes apoptosis. Cardiovasc Toxicol 2004;4:327-338.
25. Zhong DS, Lu XH, Conklin BS, Lin PH, Lumsden AB, Yao Q, Chen C: HIV protease ritonavir induces cytotoxicity of human endothelial cells. Arterioscler Thromb Vasc Biol 2002;22:1560-1566.
26. Stein JH, Klein MA, Bellehumeur JL, McBride PE, Wiebe DA, Otvos JD, Sosman JM: Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation 2001;104:257-262.
27. Twu C, Liu QN, Popik W, Bukrinsky M, Sayre J, Roberts J, Rania S, Bramhandam V, Roos KP, MacLellan WR, Fiala M: Cardiomyocytes undergo apoptosis in human immunodeficiency virus cardiomyopathy through mitochondrion and death receptor-controlled pathways. Proc Natl Acad Sci USA 2002;99:14386-14391.
28. Holmberg SD, Moorman AC, Williamson JM, Tong TC, Ward DJ, Wood KC, Greenberg AE, Janssen RS; HIV Outpatient Study (HOPS) investigators: Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet 2002;360:1747-1748.
29. Barbaro G, Di Lorenzo G, Cirelli A, Grisorio B, Lucchini A, Hazra C, Barbarini G: An open-label, prospective, observational study of the incidence of coronary artery disease in patients with HIV receiving highly active antiretroviral therapy. Clin Ther 2003;25:2405-2418.
30. Friis-Moller N, Weber R, Reiss P, Thiebaut R, Kirk O, D'Arminio Monforte A, Pradier C, Morfeldt L, Mateu S, Law M, El-Sadr W, De Witt S, Sabin CA, Phillips AN, Lundgren JD; DAD study group: Cardiovascular risk factors in HIV patients - association with antiretroviral therapy. Results from the DAD study. AIDS 2003;17:1179-1193.
31. Bozzette SA, Ake CF, Tam HK, Chang SW, Louis TA: Cardiovascular and cerebrovascular events in patients treated for human immuno-deficiency virus infection. N Engl J Med 2003;348:702-710.
32. Mary-Krause M, Cotte L, Simon A, Partisani M, Costagliola D; Clinical Epidemiology Group from the French Hospital Database: Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 2003;17:2479-2486.
33. Depairon M, Chessex S, Sudre P, Rodondi N, Doser N, Chave JP, Riesen W, Nicod P, Darioli R, Telenti A, Mooser V; Swiss HIV Cohort Study: Premature atherosclerosis in HIV-infected individuals: focus on protease inhibitor therapy. AIDS 2001;15:329-334.
34. Hsue PY, Lo JC, Franklin A, Bolger AF, Martin JN, Decks SG, Waters DD: Progression of atherosclerosis as assessed by carotid intimamedia thickness in patients with HIV infection. Circulation 2004;109:1603-1608.
35. Currier JS, Kendall MA, Zackin R, Henry WK, Alston-Smith B, Torriani F, Schouten J, Mickelberg K, Li Y, Hodis HN; AACTG 5078 Study Team: Carotid artery intima-media thickness and HIV infection: traditional risk factors overshadow impact of protease inhibitor exposure. AIDS 2005;19:927-933.
36. Maggi P, Serio G, Epifani G, Fiorentino G, Saracino A, Fico C, Perilli F, Lillo A, Ferraro S, Gargiulo M, Chirianni A, Angarano G, Regina G, Pastore G: Premature lesions of the carotid vessels in HIV-1-infected patients treated with protease inhibitors. AIDS 2000;14:F123-F128.
37. Thiebaut R, Aurillac-Lavignolle V, Bonnet F, Ibrahim N, Cipriano C, Neau D, Dupon M, Dabis F, Mercie P; Groupe d'Epidemiologie Clinique du Sida en Aquitaine (GECSA): Change in atherosclerosis progression in HIV-infected patients: ANRS Aquitane Cohort, 1999-2004. AIDS 2005;19:729-731.
38. Aoun S, Ramos E: Hypertension in the HIV-infected patient. Curr Hypertens Rep 2000;2:478-481.
39. Gazzaruso C, Bruno R, Garzaniti A, Giordanetti S, Fratino P, Sacchi P, Filice G: Hypertension among HIV patients: prevalence and relationship to insulin resistance and metabolic syndrome. J Hypertens 2003;21:1377-1382.
40. Sattler FR, Qian D, Louie S, Johnson D, Briggs W, DeQuattro V, Dube MP: Elevated blood pressure in subjects with lipodystrophy. AIDS 2001;15:2001-2010.
41. Witz M, Lehmann J, Korzets Z: Acute brachial artery thrombosis as the initial manifestation of human immunodeficiency virus infection. Am J Hematol 2000;64:137-139.
42. Hadigan C, Meigs JB, Rabe J, D'Agostino RB, Wilson PW, Lipinska I, Tofler GH, Grinspoon S: Increased PAI-1 and tPA antigen levels are reduced with metformin therapy in HIV-infected patients with fat redistribution and insulin resistance. J Clin Endocrinol Metab 2001;86:939-943.
43. Nair R, Robbs JV, Chetty R, Naidoo NG, Woolgar J: Occlusive arterial disease in HIV-infected patients: a preliminary report. Eur J Vasc Endovasc Surg 2000;20:353-357.
44. Sullivan PS, Dworkin MS, Jones JL, Hooper WC: Epidemiology of thrombosis in HIV-infected individuals. The Adult/Adolescent Spectrum of HIV Disease Project. AIDS 2000;14:321-324.
45. Miguez-Burbano MJ, Burbano X, Rodriguez A, Lecusay R, Rodriguez N, Shor-Posner G: Development of thrombocytosis in HIV+ drug users: impact of antiretroviral therapy. Platelets 2002;13:183-185.